FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2863287772> ?p ?o ?g. }

• W2863287772 endingPage "12" @default.
• W2863287772 startingPage "11" @default.
• W2863287772 abstract "Dyskeratosis congenita (DC), which is characterized by a classical triad of reticular skin pigmentation, nail dystrophy and oral leukoplakia, is an inherited bone marrow failure (BMF) syndrome (Walne & Dokal, 2009; Nishio & Kojima, 2010). BMF is a common clinical feature that usually develops within the first decade of life. DC is caused by germline mutations in telomere-associated genes and results in excessive telomere attrition. The length of telomeres in most patients with DC is less than the first percentile of telomere length in age-matched healthy individuals (Alter et al, 2007). To date, 14 genes involved in telomere biology have been identified in approximately 70% of the patients (Wegman-Ostrosky & Savage, 2017). DC is also a cancer predisposition syndrome; patients with DC are at high-risk for malignancies, such as head and neck squamous cell carcinoma (SCC), anogenital SCC, myelodysplastic syndrome (MDS) and acute myeloid leukaemia (Alter et al, 2018). The risk of BMF in DC patients is exceedingly high with a cumulative incidence of about 50% by the age of 40 years and it is the primary cause of death in these patients, followed by pulmonary fibrosis and malignant disease. Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative treatment for BMF in patients with DC; however, this cannot correct other systemic defects of telomere maintenance. Allogeneic HSCT accelerates telomere shortening (Wynn et al, 1998), thereby increasing transplant–related toxicities, including pulmonary/liver complications in patients with DC. Moreover, the risk for developing solid tumours is higher in transplanted patients than in patients without transplants (Calado & Clé, 2017). In the current issue, Fioredda et al (2018) analyse the outcome of 94 patients with DC who underwent HSCT between 1979 and 2015. A non-myeloablative conditioning regimen (NMAC) was administered to all patients. The 5-year overall survival (OS) rate was 59%; 39 patients died, accounting for a crude mortality rate of 41%. The OS curve showed a continuous decline over time; in particular, a sudden decline was observed after 8 years, with 10-year OS estimates of only <30%. The causes of death were infection (43%), organ damage (25%), rejection/graft failure (8%), secondary malignancy (8%) and others (8%). Infection and rejection/graft failure were the main causes of early deaths (i.e. within 24 months after transplantation). The incidence of organ damage particularly pulmonary fibrosis, and secondary malignancies increased later after transplantation, without reaching a plateau. Although clinical haematologists are particularly interested in the haematological findings in DC and their correction, neglecting the complex phenotype in DC patients as outlined above will most likely prove unfavourable and harmful if an allogeneic HSCT is under consideration. Traditionally, the endpoints of patients who underwent HSCT were 3- to 5-year OS; however, a continuous decline in the OS and an increase in late mortalities, even after 10 years from HSCT, were also observed in other large cohort studies involving DC patients who underwent HSCT (Gadalla et al, 2013; Barbaro & Vedi, 2016). The long-term outcome was disappointing, with an estimated OS of <20%. Underlying pulmonary and hepatic disease may predispose the patients to increased transplantation-related morbidity and mortality. Early results with NMAC were promising for improving the short-term survival (Nishio et al, 2011); however, there was no positive impact on long-term survival (Barbaro & Vedi, 2016). These disappointing results raise the question; “Should we consider HSCT as the first-line treatment for patients with DC?” The treatment of DC should aim at not only curing BMF but also prevent other organ damage and reduce the risk for cancer in affected patients. Since the 1960's, androgens have been a therapeutic option for both inherited and acquired BMF syndromes when there is no evidence of progression to MDS or acute leukaemia. An in vitro study reported that androgen up-regulates both telomerase reverse transcriptase gene expression and telomerase enzymatic activity of human lymphocytes and CD34+ haematopoietic cells (Calado et al, 2009). In a prospective phase 1/2 study, Townsley et al (2016) administered danazol to 27 patients with DC. All 12 evaluated patients demonstrated telomere elongation. Haematological responses occurred in 19 of 24 patients (79%) at 3 months and in 10 of 12 patients (83%) at 24 months. It is also very promising that the pulmonary fibrosis score, based on high-resolution computed tomography, and the diffusing capacity of the lung for carbon monoxide (DLCO) were stable in 25 patients who had a DLCO defect during the 2 years of danazol therapy. The attenuation of telomere attrition may abrogate chromosome instability and decrease the risk of secondary malignancies. These new data regarding HSCT and danazol treatment in patients with DC raise the need for a prospective study comparing patients who undergo HSCT and those administered danazol as the first-line therapy. Further studies investigating the prophylactic use of danazol after HSCT to increase telomere activity and decrease the incidence of late mortality due to pulmonary fibrosis and second malignancies are warranted." @default.
• W2863287772 created "2018-07-19" @default.
• W2863287772 creator A5013190832 @default.
• W2863287772 creator A5015904741 @default.
• W2863287772 date "2018-07-05" @default.
• W2863287772 modified "2023-09-24" @default.
• W2863287772 title "Reconsidering the indication of haematopoietic stem cell transplantation for dyskeratosis congenita" @default.
• W2863287772 cites W1973627263 @default.
• W2863287772 cites W2003562932 @default.
• W2863287772 cites W2028754058 @default.
• W2863287772 cites W2045121825 @default.
• W2863287772 cites W2094257984 @default.
• W2863287772 cites W2162194231 @default.
• W2863287772 cites W2295295999 @default.
• W2863287772 cites W2394724717 @default.
• W2863287772 cites W2588865924 @default.
• W2863287772 cites W2766801595 @default.
• W2863287772 cites W2779449343 @default.
• W2863287772 cites W2822017529 @default.
• W2863287772 doi "https://doi.org/10.1111/bjh.15493" @default.
• W2863287772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29978455" @default.
• W2863287772 hasPublicationYear "2018" @default.
• W2863287772 type Work @default.
• W2863287772 sameAs 2863287772 @default.
• W2863287772 citedByCount "4" @default.
• W2863287772 countsByYear W28632877722020 @default.
• W2863287772 countsByYear W28632877722021 @default.
• W2863287772 countsByYear W28632877722022 @default.
• W2863287772 countsByYear W28632877722023 @default.
• W2863287772 crossrefType "journal-article" @default.
• W2863287772 hasAuthorship W2863287772A5013190832 @default.
• W2863287772 hasAuthorship W2863287772A5015904741 @default.
• W2863287772 hasBestOaLocation W28632877721 @default.
• W2863287772 hasConcept C109159458 @default.
• W2863287772 hasConcept C126322002 @default.
• W2863287772 hasConcept C142724271 @default.
• W2863287772 hasConcept C143998085 @default.
• W2863287772 hasConcept C177336024 @default.
• W2863287772 hasConcept C203014093 @default.
• W2863287772 hasConcept C2777408962 @default.
• W2863287772 hasConcept C2779285011 @default.
• W2863287772 hasConcept C2780525284 @default.
• W2863287772 hasConcept C28328180 @default.
• W2863287772 hasConcept C2911091166 @default.
• W2863287772 hasConcept C54355233 @default.
• W2863287772 hasConcept C552990157 @default.
• W2863287772 hasConcept C71924100 @default.
• W2863287772 hasConcept C86803240 @default.
• W2863287772 hasConceptScore W2863287772C109159458 @default.
• W2863287772 hasConceptScore W2863287772C126322002 @default.
• W2863287772 hasConceptScore W2863287772C142724271 @default.
• W2863287772 hasConceptScore W2863287772C143998085 @default.
• W2863287772 hasConceptScore W2863287772C177336024 @default.
• W2863287772 hasConceptScore W2863287772C203014093 @default.
• W2863287772 hasConceptScore W2863287772C2777408962 @default.
• W2863287772 hasConceptScore W2863287772C2779285011 @default.
• W2863287772 hasConceptScore W2863287772C2780525284 @default.
• W2863287772 hasConceptScore W2863287772C28328180 @default.
• W2863287772 hasConceptScore W2863287772C2911091166 @default.
• W2863287772 hasConceptScore W2863287772C54355233 @default.
• W2863287772 hasConceptScore W2863287772C552990157 @default.
• W2863287772 hasConceptScore W2863287772C71924100 @default.
• W2863287772 hasConceptScore W2863287772C86803240 @default.
• W2863287772 hasIssue "1" @default.
• W2863287772 hasLocation W28632877721 @default.
• W2863287772 hasLocation W28632877722 @default.
• W2863287772 hasOpenAccess W2863287772 @default.
• W2863287772 hasPrimaryLocation W28632877721 @default.
• W2863287772 hasRelatedWork W1987143542 @default.
• W2863287772 hasRelatedWork W1994932701 @default.
• W2863287772 hasRelatedWork W2026180657 @default.
• W2863287772 hasRelatedWork W2037951294 @default.
• W2863287772 hasRelatedWork W2118999391 @default.
• W2863287772 hasRelatedWork W2118999711 @default.
• W2863287772 hasRelatedWork W2766421436 @default.
• W2863287772 hasRelatedWork W2903324843 @default.
• W2863287772 hasRelatedWork W3047315811 @default.
• W2863287772 hasRelatedWork W4236724632 @default.
• W2863287772 hasVolume "183" @default.
• W2863287772 isParatext "false" @default.
• W2863287772 isRetracted "false" @default.
• W2863287772 magId "2863287772" @default.
• W2863287772 workType "article" @default.